IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/017,755

Filed:

October 30, 2001

1st Inventor:

T. Shimizu

For:

Orally Disintegrable Tablets

Atty. Dkt. No.

2522 US2P

Art Unit:

1615

Examiner:

S. Tran

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants' request consideration of the reference listed on the attached form PTO-1449 under §1.97(b).

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' attorney.

Respectfully submitted,

Dated: December 14, 2004

(847) 383-3391

(847) 383-3372

Elain M Kamesh Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ubstitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Cor	nplete if Known	
Application Number	10/017,755	
Filing Date	October 30, 2001	
First Named Inventor	T. Shimizu	
Art Unit	1615	
Examiner Name	S. Tran	
Attorney Docket Number	2522 US2P	

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 4,371,516	02-01-1983	John Wyeth & Brother Limited	
		^{US-} 5,795,909	08-08-1998	Neuromedica, Inc.	,
		^{US-} 5,958,453	09-28-1999	Takeda Chemical Industries	
		^{US-} 5,900,428	05-04-1999	Astra Aktiebolag	
		^{US-} 6,248,357	06-19-2001	Takeda Chemical Industries	
		^{US-} 6,287,596	09-11-2001	Daiichi Pharmaceutical Co.	·
		^{US-} 6,365,184	04-02-2002	AstraZeneca AB	
		^{US-} 6,328,994	12-11-2001	Takeda Chemical Industries	
		^{US-} 6,586,004	07-01-2003	Takeda Chemical Industries	
		US-			
	-	US-			
		US-			1
		US-			

		FORE	IGN PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		EP 0 336 298	03-30-1989	E. R. Squibb & Sons		
		EP 0 345 787 /	06-08-1989	Warner-Lambert Company		
		EP 0 365 480 /	10-10-1989	CIBA-GEIGY AG		
		EP 0 438 147	01-17-1991	SCLAVO S.p.A.		
•		EP 0 553 777 /	01-27-1993	Takeda Chemical Industries		
		EP 0 638 310 /	07-26-1994	Bristol-Myers Squibb Co.		

Examiner	Date	e	-
Signature	1 <u>-</u>	nsidered	
-		I	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/017,755				
Filing Date	October 30, 2001				
First Named Inventor	T. Shimizu				
Art Unit	1615				
Examiner Name	S. Tran				
Attorney Docket Number	2522 US2P				

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}			Figures Appear
		US-			
		US-			
	i	US-			
		US-			
		US-			
		US-	1		
		US-			
-		US-			
		US-			
		US-			
		US-			
		US-	† ·	•	
		US-			
		US-			
		US-	-		

		FORE	IGN PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		EP 0 745 382 ~	01-27-1995	Yamanouchi Pharmaceutical		
•		EP 0 839 526 ~	10-29-1997	Takeda Chemical Industries		
		EP 0 890 359 ~	02-21-1997	Fujisawa Pharmaceutical Co.		L
		EP 0 914 818	06-12-1997	Kyowa Hakko Kogyo Co., Ltd		
		EP 0 922 464 /	07-10-1997	Daiichi Pharmaceutical Co.		
		EP 0 965 339 /	11-14-1997	Aijnomoto Co., Inc.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known						
<u>*</u>						
Application Number	10/017,755					
Filing Date	October 30, 2001					
First Named Inventor	T. Shimizu					
Art Unit	1615					
Examiner Name	S. Tran					
Attorney Docket Number	2522 US2P					

			U. S. PATENT D		
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
· · · · · · · · · · · · · · · · · · ·	-	Number-Kind Code ^{2 (# known)} US-		· · · · · · · · · · · · · · · · · · ·	·
		05-			1
		US-			
		US-		•	
		US-			
	-	US-			
		US-			
· · · · · · · · · · · · · · · · · · ·		US-	1		
		US-			
		US-			
		US-			
·		US-			
		US-			
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			-

		FOREIG	SN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO 92/11001 /	07-09-1992	SOLVAY (Societe Anonyme)		
		JP 4 066 538 (Abstract Only) /	03-02-1992	Suntory Ltd.		V
		JP 5 310 558 (Abstract Only) /	11-22-1993	Lion Corp.		V
		JP 5 411 226 (Abstract Only) /	01-27-1979	Shinetsu Chemical Industries		V
		JP 6 100 601 (Abstract Only) >	04-12-1994	Daicel Chemical Industries		~
		JP 6 305 962 (Abstract Only) /	04-21-1993	Taisho Pharmaceut Co. Ltd.		V

Examiner	Date	
	500	
Signature	Considered	
Oignature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete, this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/017,755	
Filing Date	October 30, 2001	
First Named Inventor	T. Shimizu	
Art Unit	1615	
Examiner Name	S. Tran	
Attorney Docket Number	2522 US2P	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<u> </u>	Number-Kind Code ^{2 (f known)}			rigules Appeal
	i	US-			
		US-			
		US-			
		US-			****
		US-			
		US-		- · · · · · · · · · · · · · · · · · · ·	
		US-	 		
		US-	 	· · · · · · · · · · · · · · · · · · ·	
	<u> </u>	US-	† · · · · · †		
		US-			
		US-	<u> </u>		
		US-			
		US-			
	 	US-			

		FOREIG	N PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		JP 7 017 853 (Abstract Only) -	01-20-1995	Akiyoshi Yanagida		V
		JP 8 310 969 (Abstract Only)	11-26-1996	Lion Corp. (Lioy)		V
			•			
		·				

Examiner	 Date	- · · · ·
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Subcratice for form 1449/PTO		re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
		Application Number	10/017,755		
INFO	ORMATIC	N DIS	CLOSURE	Filing Date	October 30, 2001
STATEMENT BY APPLICANT		First Named Inventor	T. Shimizu		
(1)			occessed	Art Unit	1615
(Use as many sheets as necessary)		Examiner Name	S. Tran		
Sheet	1	of	1	Attorney Docket Number	2522 US2P

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title the item (book, magazine, journal, serial, symposium, canumber(s), publisher, city and/or cour	talog, etc.), date,	page(s), volume-issue	T²
		Watanabe, Y. et al., "New Compressed Tablet Rapidly Dis Crystalline Cellulose and a Disintegrant", Biol. Pharm. Bul			
					-
		·			
			, , , , , , , , , , , , , , , , , , ,		
					,
Examiner			Date		1

	
Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.